MEDIPAL HOLDINGS CORPORATION and JCR Pharmaceuticals Dose First Patient in Global Phase I/II Trial of JR-446 for Mucopolysaccharidosis Type IIIB

Posted on by sHq_LoGiNz

TOKYO & HYOGO, Japan–(BUSINESS WIRE)–JCR and MEDIPAL announced that the first participant has been dosed in the global Phase I/II trial of JR-446 for mucopolysaccharidosis type IIIB.

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.